(Nasdaq: NK), a clinical-stage, natural killer cell-based therapeutics company, and ImmunityBio, a privately held immunotherapy company, today announced the signing of a definitive agreement to jointly develop, manufacture, market, and commercialize therapeutics and vaccines for combating the ...
Foresee Pharmaceuticals announced that it has entered into an exclusive license agreement with GenScience Pharmaceuticals - a wholly-owned subsidiary of Changchun High-Tech Industry Co., Ltd.
China will deepen the implementation of innovation-driven development strategy. The integration of basic research, applied research and technological innovation will be promoted to accelerate the development of strategic emerging industries, Wang said in the preface. Moreover, the service system for comme...
Arcturus Therapeutics is a global late-stage clinical messenger RNA medicines and vaccines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines.
For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to delive...
(Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that Merck has exercised its option to jointly dev...
co-development, joint commercialization, and marketing of BioVaxys vaccines for ovarian cancer, cervical cancer, and human papilloma virus ("HPV"), and the right of first refusal for marketing by BioVaxys inthe United Stateso...
COVID WILDCARD Companies in the cell and gene therapy market must be aware of significant headwinds caused by the global COVID-19 pandemic. COVID-19 has caused considerable supply chain disruptions. In particular, the reduced availability of active pharmaceutical ingredients and...